Science Explorer Back to mapMap

Most cited papers from Bicycle Therapeutics (United Kingdom)

What are the most cited papers from Bicycle Therapeutics (United Kingdom)?

The most cited paper from Bicycle Therapeutics (United Kingdom) is "Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial" (Stephen R.D. Johnston et al., 2018), with 239 citations. Next come "MMAE Delivery Using the Bicycle Toxin Conjugate BT5528" (102) and "BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors" (80).

Showing 50 of 86 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial Stephen R.D. Johnston et al. · Journal of Clinical Oncology Open access 6 Dec 2018 239
2 MMAE Delivery Using the Bicycle Toxin Conjugate BT5528 Gavin S. Bennett, Amy N. Brown, Gemma Mudd et al. · Molecular Cancer Therapeutics 12 May 2020 102
3 BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors Michael Rigby, Gavin S. Bennett, Liuhong Chen et al. · Molecular Cancer Therapeutics Open access 16 Sep 2022 80
4 Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases Vanessa Baeriswyl, Helen Rapley, Lisa Pollaro et al. · ChemMedChem Open access 11 Apr 2012 73
5 Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors Matthias Eder, Silvia Pavan, Ulrike Bauder‐Wüst et al. · Cancer Research 3 Jan 2019 69
6 Antimicrobial and Cell-Penetrating Peptides: Understanding Penetration for the Design of Novel Conjugate Antibiotics Andreas Hadjicharalambous, Nikolaos Bournakas, Hector Newman et al. · Antibiotics Open access 16 Nov 2022 62
7 Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema Daniel P. Teufel, Gavin S. Bennett, Helen Harrison et al. · Journal of Medicinal Chemistry Open access 8 Mar 2018 45
8 BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism Kristen E. Hurov, Johanna Lahdenranta, Punit Upadhyaya et al. · Journal for ImmunoTherapy of Cancer Open access Nov 2021 38
9 Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma Yifei Wang et al. · Molecular Cancer Therapeutics Open access 21 Mar 2022 34
10 Development of a Lc–Ms/Ms Method for the Quantification of Toxic Payload Dm1 Cleaved from Bt1718 in a Phase I Study Catherine Gowland, Philip Berry, Julie Errington et al. · Bioanalysis Open access 2021 34
11 Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist Punit Upadhyaya et al. · Journal for ImmunoTherapy of Cancer Open access 2021 32
12 Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer Laura M. Spring, Hyo Sook Han, Minetta C. Liu et al. · Nature Cancer Open access 4 Jul 2022 31
13 Disease-relevant β2-microglobulin variants share a common amyloid fold Martin Wilkinson, Rodrigo U. Gallardo, Roberto Maya‐Martinez et al. · Nature Communications Open access 2 Mar 2023 30
14 Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC Michael L. Cheng, Christie J. Lau, Marina S.D. Milan et al. · JCO Precision Oncology Open access 17 Feb 2021 29
15 A hospital led promotion campaign aimed to increase bicycle helmet wearing among children aged 11–15 living in West Berkshire 1992–98 Angela J. Lee, Nicholas P. Mann, Rachel Allison Takriti · Injury Prevention Open access Jun 2000 29
16 Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide Mohamed El Fakiri, Anusha R. Regupathy, Lisa Uhlmann et al. · Theranostics Open access 2024 26
17 Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2 Katherine U. Gaynor et al. · Nature Communications Open access 16 Jun 2023 26
18 Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors Babar Bashir, Judy S. Wang, Gerald Steven Falchook et al. · Journal of Clinical Oncology Open access 4 Sep 2024 25
19 Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles Michael E. Østergaard et al. · Nucleic Acids Research Open access 10 Apr 2025 23
20 Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics Klara Livia Valko, Gabriela Ivanova-Berndt, Paul Beswick et al. · ADMET & DMPK Open access 7 Jun 2018 23
21 Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology Punit Upadhyaya, Julia Kristensson, Johanna Lahdenranta et al. · Journal of Medicinal Chemistry Open access 12 Jul 2022 22
22 DirectMX – One-Step Reconstitution of Membrane Proteins From Crude Cell Membranes Into Salipro Nanoparticles Pilar Lloris-Garcerá, Stefan Klinter, Liuhong Chen et al. · Frontiers in Bioengineering and Biotechnology Open access 19 Mar 2020 20
23 Novel immunotherapeutics against LGR5 to target multiple cancer types Hung‐Chang Chen et al. · EMBO Molecular Medicine Open access 21 Aug 2024 19
24 First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation Capucine Baldini et al. · Journal of Clinical Oncology Open access 6 Nov 2025 15
25 Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides Gemma Mudd, Steven J. Stanway, David R. Witty et al. · Bioconjugate Chemistry 27 Jul 2022 15
26 A C-terminal cysteine residue is required for peptide-based inhibition of the NGF/TrkA interaction at nM concentrations: implications for peptide-based analgesics Andrew J. Poole, Laura Frigotto, Matthew Edward Smith et al. · Scientific Reports Open access 30 Jan 2019 10
27 Exploring force-driven stochastic folding dynamics in mechano-responsive proteins and implications in phenotypic variation Pritam Saha, Vishavdeep Vashisht, Ojas Singh et al. · Nature Communications Open access 25 Jan 2025 7
28 652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1 O. Reig Torras, Laurence Crouzet, Andrea Necchi et al. · Annals of Oncology Open access Sep 2024 7
29 599TiP BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies Meredith Ann McKean, Johanna C. Bendell, Daniel Peter Petrylak et al. · Annals of Oncology Open access Sep 2020 7
30 Disposition of Biologics Kevin Brady, Rob Webster · Advances in pharmacology Book chapter 2012 7
31 NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors Farzaneh‐Sadat Rezazadeh‐Shojaee, Esmaeel Azadian, Min Xian Wong et al. · Science Advances Open access 9 Jul 2025 6
32 Bioanalysis of the Bicycle®Toxin Conjugate BT5528 and Released Monomethyl Auristatin E via Liquid Chromatography–Tandem Mass Spectrometry Joseph A. Tweed, Fern Adams-Dam, Jane Allanson et al. · Bioanalysis 13 Dec 2023 6
33 An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics James Mark Wagstaff, Matthew R. Balmforth, Nick Lewis et al. · ACS Infectious Diseases 22 Jul 2020 6
34 Bicycle helmets: their role in injury prevention Nicholas P. Mann, A.J. Lee · Current Paediatrics Sep 1999 6
35 2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates ( PART 1A – Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Valida John Wojcik et al. · Bioanalysis Open access 17 Dec 2025 5
36 647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study Emily Fontana, J.S. Wang, Meredith Ann McKean et al. · Annals of Oncology Open access Sep 2024 5
37 Radial Stiffness and Damping of Mountain Bike Tires Subject to Impact Determined Using the Coefficient of Restitution James Sadauckas, Noah Schoeneck, Mark L. Nagurka · The Evolving Scholar Open access 2023 5
38 Cycle helmets A J Lee · Archives of Disease in Childhood Open access 23 May 2003 5
39 96P: Enhanced anti-tumor activity of zelenectide pevedotin in patients (pts) with non-small cell lung cancer (NSCLC) with NECTIN4 gene amplification (amp) Loïc Verlingue, N. Klümper, M. Eckstein et al. · Journal of Thoracic Oncology Open access Mar 2025 4
40 654P Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors Bernard Doger de Spéville, Meredith Ann McKean, C. Baldini et al. · Annals of Oncology Open access Sep 2024 4
41 650P Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors Kyriakos P. Papadopoulos, Afshin Dowlati, Juanita Suzanne Lopez et al. · Annals of Oncology Open access Sep 2024 4
42 Sarcopenia in colorectal cancer is related to socio-economic deprivation and Body Mass Index alone misrepresents underlying muscle loss in the deprived Edward Tobias Pring, Laura E. Gould, George Malietzis et al. · Clinical Nutrition ESPEN 10 Jun 2024 3
43 Identification and Modeling of a Mountain Bike Front Suspension Subsystem Equipped with a Telescopic Fork and Tire Damping Noah Schoeneck, James Sadauckas, Mark L. Nagurka Conference paperOpen access 25 Sep 2023 3
44 Nondegenerate Saturation Mutagenesis: Library Construction and Analysis via MAX and ProxiMAX Randomization Anupama Chembath, Ben P. G. Wagstaffe, Ashraf Mohammed et al. · Methods in molecular biology Book chapter 2022 3
45 USING A RIDE TO WORK DAY EVENT TO PROMOTE TRAVEL BEHAVIOUR CHANGE Geoff Rose, Heidi Marfurt, Phil Harbutt 2003 3
46 Small siphophage binding to an open state of the LptDE outer membrane lipopolysaccharide translocon Emily Dunbar, Robert L. Clark, Arnaud Baslé et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 7 Jul 2025 2
47 A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2). Yohann Loriot, Arlene Odelia Siefker-Radtke, Terence W. Friedlander et al. · Journal of Clinical Oncology 10 Feb 2025 2
48 The validation and clinical bioanalysis of the Bicycle® Toxin Conjugate zelenectide pevedotin in human plasma Joseph A. Tweed, Fern Adams-Dam, Justin Bader et al. · Bioanalysis Open access 19 Jan 2025 2
49 Gluebodies improve crystal reliability and diversity through transferable nanobody mutations that introduce constitutive close contacts Mingda Ye, Mpho Makola, Joseph A. Newman et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 26 Jul 2022 2
50 Bike Sharing System in Shanghai:Planning & Practice Ming Shou Zhong · Urban Transport of China 2009 2

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.